Abstrakt: |
RADNOR, Pa., Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs. She will lead the Company's clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director. [ABSTRACT FROM PUBLISHER] |